Innovation Grants Program
Ready to advance your research? Apply for our Innovation Grants Program and gain access to cutting-edge tumor infiltration prediction that could accelerate your cell therapy development process.
Advancing Immune Therapy Research
Infiltrate Bio provides funding opportunities for tumor infiltration and related research areas through our adhesion biomarker platform. Our advanced adhesion chromatography platform enables researchers to predict immune cell tumor homing potential in all stages of the development pipeline. We invite researchers, innovators, and consortia to submit proposals that explore novel applications of tumor infiltration prediction in cell therapy development, immunotherapy optimization, or other relevant fields.
Who Should Apply?
This grant is open to researchers, academic institutions, biotech companies, and pharmaceutical partners looking to integrate cutting-edge tumor infiltration prediction technology into their work. Applicants should have a strong scientific rationale and a clear plan for utilizing Infiltrate Bio's adhesion biomarker platform.
Application Process
Applications are reviewed on a rolling basis throughout the year. Submit a 250-word proposal outlining your project objectives, research plan, and relevance to immune infiltration.
Review cycles occur on a rolling basis with notifications sent within 4-6 weeks of submission.
Grant Details
Our Innovation Grants support pilot studies analyzing primary T cells, CAR-T cells, PBMCs, or other immune cell populations.
Program details
Service Access
Infiltration biomarker analysis service with our adhesion chromatography platform
Sample Capacity
Up to 20 immune cell samples per pilot study
Data Package
Comprehensive analysis report with infiltration predictions, adhesion metrics, and expert interpretation
Scientific Support
Consultation on experimental design, data analysis, and results interpretation
Timeline
All samples must be submitted to Infiltrate Bio within 3 months of grant acceptance
Accepted Sample Types (choose one category per application)
Primary T cells: CD4+, CD8+, or mixed T cell populations
Engineered cells: CAR-T, TCR-T, or other genetically modified immune cells
PBMCs: Peripheral blood mononuclear cells or other immune cell preparations
Program Requirements
Eligibility
Open to researchers affiliated with academic institutions, biotechnology companies, or pharmaceutical organizations
Scientific Dissemination
Grant recipients are expected to share results through publication, conference presentation, or poster presentation at a relevant scientific conference within 12 months of grant acceptance
Submit Your Application
Applications are accepted on a rolling basis. Start your research innovation today.
Terms and Conditions Apply.